2025 Q3 -tulosraportti
88 päivää sitten56 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
253 741
Myynti
Määrä
246 895
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 322 | - | - | ||
| 977 | - | - | ||
| 1 793 | - | - | ||
| 955 | - | - | ||
| 58 | - | - |
Ylin
341VWAP
Alin
331,6VaihtoMäärä
175,2 525 975
VWAP
Ylin
341Alin
331,6VaihtoMäärä
175,2 525 975
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 20.10.2025 | |
| 2025 Q2 -tulosraportti | 16.7.2025 | |
| 2025 Q1 -tulosraportti | 29.4.2025 | |
| 2024 Q4 -tulosraportti | 5.2.2025 | |
| 2024 Q3 -tulosraportti | 24.10.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenWhy is it interpreted differently? 1. Fundamentally: Very strong announcement Analysts and long-term investors see this as: A sign that Sobi has stronger momentum than expected. That the margin expansion is structural, not just temporary. That important products (Doptelet, Gamifant) exceed expectations. That is why the stock initially rose clearly. 2. Market reaction: Short-term rise – then decline Despite strong figures, the stock quickly fell back and traded down approx. 2 %. This creates room for interpretation: Interpretation A: “Buy the rumor, sell the news” The market may have priced in improved figures already earlier. When the news came, short-term players took home profits. Interpretation B: Uncertainty ahead of the Q4 report on February 5 The press release provides topline figures, but: No details on cash flow No details on costs No updates on pipeline or regulatory risks Some investors are therefore waiting for the complete picture. Interpretation C: The market is worried about the 2026 guidance There is a risk that: 2025 became “peak margin” The 2026 guidance may be more cautious Growth may normalize after a strong Q4 This leads some to interpret the press release as “good, but not enough to change the long-term view”. 3. Psychological factor: Sobi is a company where the market is often skeptical Sobi has historically: Had volatility in sales Delivered mixed results in the pipeline Been subject to acquisition speculation This means the market sometimes reacts more cautiously than the figures warrant.
·39 min sittenI think that if a company or person has a very good and stable product, or several, as in Sobi's case, it doesn't matter if one reports on cash flow and other things that are actually completely irrelevant for the future. That you, Jesse, and the rest of us want to make money on our investments is obvious. But I think one step further than just making money. What Sobi does is about helping people with difficult, rare diseases to a better life. That is what I hope their objective is. If they succeed, we all gain something. I invest in companies I believe can contribute to a better future. Money can never be your biggest driving force. If it is, one will soon stand alone at the edge of the cliff. I believe Sobi has something good for all of us. Take care. Regards P- ·1 päivä sittenIt is sometimes very strange how the market (people) acts and reacts to different news. What is incredibly positive news and great confidence in the future should be met with the response and respect the news deserves, I think. In Sobi's case, it's often the opposite for some reason. In fact, this often happens in credible, serious companies. What figures does the market actually expect? It becomes completely unreasonable. Have a nice day!·1 päivä sittenThat's how it is, Jessel. But interpreting facts and acting on emotions is not assessing things for what they truly are. Perhaps that's why companies with weak products and performance attract so many to bad investments. A question, what in this do you see as negative?
·9.1.Shouldn't this shares be higher?·9.1.Yes, one can really wonder after the pronouncements about their fantastic drug, which is predicted to become world-leading. One has to take everything with a pinch of salt if one doesn't have the knowledge to assess it oneself.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
88 päivää sitten56 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenWhy is it interpreted differently? 1. Fundamentally: Very strong announcement Analysts and long-term investors see this as: A sign that Sobi has stronger momentum than expected. That the margin expansion is structural, not just temporary. That important products (Doptelet, Gamifant) exceed expectations. That is why the stock initially rose clearly. 2. Market reaction: Short-term rise – then decline Despite strong figures, the stock quickly fell back and traded down approx. 2 %. This creates room for interpretation: Interpretation A: “Buy the rumor, sell the news” The market may have priced in improved figures already earlier. When the news came, short-term players took home profits. Interpretation B: Uncertainty ahead of the Q4 report on February 5 The press release provides topline figures, but: No details on cash flow No details on costs No updates on pipeline or regulatory risks Some investors are therefore waiting for the complete picture. Interpretation C: The market is worried about the 2026 guidance There is a risk that: 2025 became “peak margin” The 2026 guidance may be more cautious Growth may normalize after a strong Q4 This leads some to interpret the press release as “good, but not enough to change the long-term view”. 3. Psychological factor: Sobi is a company where the market is often skeptical Sobi has historically: Had volatility in sales Delivered mixed results in the pipeline Been subject to acquisition speculation This means the market sometimes reacts more cautiously than the figures warrant.·39 min sittenI think that if a company or person has a very good and stable product, or several, as in Sobi's case, it doesn't matter if one reports on cash flow and other things that are actually completely irrelevant for the future. That you, Jesse, and the rest of us want to make money on our investments is obvious. But I think one step further than just making money. What Sobi does is about helping people with difficult, rare diseases to a better life. That is what I hope their objective is. If they succeed, we all gain something. I invest in companies I believe can contribute to a better future. Money can never be your biggest driving force. If it is, one will soon stand alone at the edge of the cliff. I believe Sobi has something good for all of us. Take care. Regards P
- ·1 päivä sittenIt is sometimes very strange how the market (people) acts and reacts to different news. What is incredibly positive news and great confidence in the future should be met with the response and respect the news deserves, I think. In Sobi's case, it's often the opposite for some reason. In fact, this often happens in credible, serious companies. What figures does the market actually expect? It becomes completely unreasonable. Have a nice day!·1 päivä sittenThat's how it is, Jessel. But interpreting facts and acting on emotions is not assessing things for what they truly are. Perhaps that's why companies with weak products and performance attract so many to bad investments. A question, what in this do you see as negative?
- ·9.1.Shouldn't this shares be higher?·9.1.Yes, one can really wonder after the pronouncements about their fantastic drug, which is predicted to become world-leading. One has to take everything with a pinch of salt if one doesn't have the knowledge to assess it oneself.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
253 741
Myynti
Määrä
246 895
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 322 | - | - | ||
| 977 | - | - | ||
| 1 793 | - | - | ||
| 955 | - | - | ||
| 58 | - | - |
Ylin
341VWAP
Alin
331,6VaihtoMäärä
175,2 525 975
VWAP
Ylin
341Alin
331,6VaihtoMäärä
175,2 525 975
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 20.10.2025 | |
| 2025 Q2 -tulosraportti | 16.7.2025 | |
| 2025 Q1 -tulosraportti | 29.4.2025 | |
| 2024 Q4 -tulosraportti | 5.2.2025 | |
| 2024 Q3 -tulosraportti | 24.10.2024 |
2025 Q3 -tulosraportti
88 päivää sitten56 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 20.10.2025 | |
| 2025 Q2 -tulosraportti | 16.7.2025 | |
| 2025 Q1 -tulosraportti | 29.4.2025 | |
| 2024 Q4 -tulosraportti | 5.2.2025 | |
| 2024 Q3 -tulosraportti | 24.10.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenWhy is it interpreted differently? 1. Fundamentally: Very strong announcement Analysts and long-term investors see this as: A sign that Sobi has stronger momentum than expected. That the margin expansion is structural, not just temporary. That important products (Doptelet, Gamifant) exceed expectations. That is why the stock initially rose clearly. 2. Market reaction: Short-term rise – then decline Despite strong figures, the stock quickly fell back and traded down approx. 2 %. This creates room for interpretation: Interpretation A: “Buy the rumor, sell the news” The market may have priced in improved figures already earlier. When the news came, short-term players took home profits. Interpretation B: Uncertainty ahead of the Q4 report on February 5 The press release provides topline figures, but: No details on cash flow No details on costs No updates on pipeline or regulatory risks Some investors are therefore waiting for the complete picture. Interpretation C: The market is worried about the 2026 guidance There is a risk that: 2025 became “peak margin” The 2026 guidance may be more cautious Growth may normalize after a strong Q4 This leads some to interpret the press release as “good, but not enough to change the long-term view”. 3. Psychological factor: Sobi is a company where the market is often skeptical Sobi has historically: Had volatility in sales Delivered mixed results in the pipeline Been subject to acquisition speculation This means the market sometimes reacts more cautiously than the figures warrant.·39 min sittenI think that if a company or person has a very good and stable product, or several, as in Sobi's case, it doesn't matter if one reports on cash flow and other things that are actually completely irrelevant for the future. That you, Jesse, and the rest of us want to make money on our investments is obvious. But I think one step further than just making money. What Sobi does is about helping people with difficult, rare diseases to a better life. That is what I hope their objective is. If they succeed, we all gain something. I invest in companies I believe can contribute to a better future. Money can never be your biggest driving force. If it is, one will soon stand alone at the edge of the cliff. I believe Sobi has something good for all of us. Take care. Regards P
- ·1 päivä sittenIt is sometimes very strange how the market (people) acts and reacts to different news. What is incredibly positive news and great confidence in the future should be met with the response and respect the news deserves, I think. In Sobi's case, it's often the opposite for some reason. In fact, this often happens in credible, serious companies. What figures does the market actually expect? It becomes completely unreasonable. Have a nice day!·1 päivä sittenThat's how it is, Jessel. But interpreting facts and acting on emotions is not assessing things for what they truly are. Perhaps that's why companies with weak products and performance attract so many to bad investments. A question, what in this do you see as negative?
- ·9.1.Shouldn't this shares be higher?·9.1.Yes, one can really wonder after the pronouncements about their fantastic drug, which is predicted to become world-leading. One has to take everything with a pinch of salt if one doesn't have the knowledge to assess it oneself.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
253 741
Myynti
Määrä
246 895
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 322 | - | - | ||
| 977 | - | - | ||
| 1 793 | - | - | ||
| 955 | - | - | ||
| 58 | - | - |
Ylin
341VWAP
Alin
331,6VaihtoMäärä
175,2 525 975
VWAP
Ylin
341Alin
331,6VaihtoMäärä
175,2 525 975
Välittäjätilasto
Dataa ei löytynyt